Understanding CAS No. 171596-29-5: A Comprehensive Look at Tadalafil
Tadalafil, identified by the CAS Number 171596-29-5, is a pharmaceutical compound widely known for its role in treating erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). As a member of the phosphodiesterase type 5 (PDE5) inhibitor class of drugs, Tadalafil has gained prominence for its unique pharmacological properties and extended duration of action. This article explores its chemical nature, mechanism of action, therapeutic uses, side effects, and regulatory context—serving as a comprehensive guide to this significant compound.
Chemical Profile
Its IUPAC name is (6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione.
Tadalafil belongs to the chemical class of carbolines, a subgroup of alkaloids. The drug's structure is designed to selectively inhibit the PDE5 enzyme, resulting in increased levels of cyclic guanosine monophosphate (cGMP) in smooth muscle tissue.
Mechanism of Action
Tadalafil’s primary pharmacological action is inhibition of the PDE5 enzyme, which is responsible for the breakdown of cGMP. In the presence of sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum of the penis. NO activates the enzyme guanylate cyclase, which leads to increased levels of cGMP.
By preventing the degradation of cGMP, Tadalafil supports sustained smooth muscle relaxation and vasodilation. What distinguishes Tadalafil from other PDE5 inhibitors is its prolonged half-life of 17.5 hours, allowing its effects to last up to 36 hours in some individuals. This extended duration has earned it the colloquial nickname “the weekend pill.”
Therapeutic Applications
Tadalafil is prescribed for multiple conditions beyond erectile dysfunction. The following are its primary therapeutic applications:
1. Erectile Dysfunction (ED)
Unlike on-demand medications, it can be taken once daily at a lower dose, offering continuous efficacy and spontaneity in sexual activity.
2. Benign Prostatic Hyperplasia (BPH)
Tadalafil has been approved for the treatment of BPH, a condition characterized by the enlargement of the prostate gland. By relaxing the smooth muscle in the bladder and prostate, it helps reduce symptoms such as urinary urgency and frequency.
3. Pulmonary Arterial Hypertension (PAH)
Tadalafil also finds use in managing pulmonary arterial hypertension. It relaxes the pulmonary vasculature, lowering pulmonary blood pressure and improving exercise capacity in affected individuals.
Pharmacokinetics and Metabolism
After oral administration, Tadalafil is absorbed rapidly, with peak plasma concentrations typically reached within two hours. It is metabolized primarily in the liver by the CYP3A4 enzyme system, and the major metabolite is pharmacologically inactive.
The drug is excreted mostly in the feces, with a smaller portion eliminated via urine. Because of its long half-life, Tadalafil maintains therapeutic levels in the bloodstream for an extended period, which is particularly beneficial for chronic treatment regimens.
Side Effects and Precautions
Like all medications, Tadalafil is associated with potential side effects. Common adverse effects include:
- Headache
- Dyspepsia (indigestion)
- Back pain
- Muscle aches
- Nasal congestion
- Flushing
These side effects are typically mild and transient. However, more serious complications can occur, particularly in individuals with cardiovascular disease. Rare but severe side effects include:
- Priapism (prolonged erection)
- Sudden hearing loss
- Visual disturbances
- Hypotension when combined with nitrates
Tadalafil is contraindicated in patients taking nitrate medications or those with certain cardiovascular conditions due to the risk of a dangerous drop in blood pressure.
Interactions and Contraindications
Tadalafil’s interaction with drugs metabolized through the CYP3A4 pathway requires caution. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) can significantly increase plasma concentrations of Tadalafil, potentially leading to increased side effects.
Alcohol and antihypertensive medications can enhance the hypotensive effects of Tadalafil. As such, patients should be monitored when combining it with other vasodilators or antihypertensives.
Research and Developments
Ongoing research continues to explore additional uses and delivery methods for Tadalafil. Studies are investigating its potential benefits in treating conditions like Raynaud’s phenomenon, female sexual arousal disorder, and even certain forms of lower urinary tract symptoms not associated with BPH.
Moreover, alternative formulations such as orodispersible tablets and topical gels are being explored to improve ease of administration and reduce gastrointestinal side effects.
Regulatory Status and Quality Control
Tadalafil is approved for medical use in many countries and is regulated as a prescription medication. As a pharmaceutical substance, it is subject to stringent manufacturing and quality control standards. The CAS number 171596-29-5 serves as a unique identifier that allows researchers, healthcare providers, and regulatory authorities to ensure consistency and traceability in scientific and industrial applications.
Conclusion
Tadalafil (CAS No. 171596-29-5) has revolutionized the treatment landscape for erectile dysfunction, BPH, and PAH, thanks to its targeted mechanism of action and long duration of effectiveness. Its pharmacological profile, combined with extensive clinical research, makes it a critical component in the toolbox of modern medicine.
While generally well-tolerated, responsible usage under medical supervision is essential to mitigate risks and ensure optimal therapeutic outcomes. As scientific exploration continues, Tadalafil may find even broader applications in the treatment of vascular and smooth muscle-related disorders, expanding its significance beyond its current indications.
URL: For more information, visit Verdant Pharma : CAS NO 171596-29-5 (TADALAFIL)